Collaborative recommendations: the approach to diagnosis and treatment of HIV wasting.
Loss of lean body mass in patients with HIV, commonly referred to as wasting, remains a significant threat to outcome in the era of highly active antiretroviral therapy. It does not require advanced immune deficiency to progress. It is appropriate to reevaluate guidelines for diagnosis and treatment of wasting in the context of the increasing detail with which the risks and causes of HIV wasting are being understood. A wide range of therapies can be effective in preventing weight loss, but the pharmacologic options for restoring body cell mass, a key measure of HIV wasting, are far more limited. A collaborative meeting of clinicians and researchers with an interest in HIV wasting was held to evaluate published guidelines in the context of current clinical data.
Wanke
Christine
C
Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA. Christine.wanke@tufts.edu
Kotler
Donald
D
D000465:Algorithms; D019247:HIV Wasting Syndrome / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans